Zsolt Bagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zsolt Bagi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Akos Koller
From the Institute of Cardiology (T.S., N.E., T.F., E.T.P., I.E., Z.B.), University of Debrecen, Hungary; the Department of Physiology (A.K.), New York Medical College, Valhalla; and the Department of Pathophysiology, Semmelweis University, Budapest, Hungary
2 shared publications- Attila Tóth
Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
1 shared publication Eniko T. Pasztor
From the Institute of Cardiology (T.S., N.E., T.F., E.T.P., I.E., Z.B.), University of Debrecen, Hungary; the Department of Physiology (A.K.), New York Medical College, Valhalla; and the Department of Pathophysiology, Semmelweis University, Budapest, Hungary
1 shared publicationGabor Kaley
From the Department of Physiology (Z.B., W.L., T.H.N., A.K., G.K.), New York Medical College, Valhalla, NY; the Department of Pathophysiology (A.K.), Semmelweis University, Budapest, Hungary; and the Division of Clinical Physiology Z.B., N.E., A.T.), Institute of Cardiology, University of Debrecen, Debrecen, Hungary
1 shared publicationIstván Édes
From the Institute of Cardiology (T.S., N.E., T.F., E.T.P., I.E., Z.B.), University of Debrecen, Hungary; the Department of Physiology (A.K.), New York Medical College, Valhalla; and the Department of Pathophysiology, Semmelweis University, Budapest, Hungary
1 shared publicationIstván Édes
Division of Clinical Physiology, Institute of Cardiology, University of Debrecen, Debrecen H-4004, Hungary
1 shared publication
Latest Publications
- 1 September 2006
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 99 (5) , e12-7
Increased Cyclooxygenase-2 Expression and Prostaglandin-Mediated Dilation in Coronary Arterioles of Patients With Diabetes Mellitus
Based on findings of experimental models of diabetes mellitus (DM) showing increased expression of vascular cyclooxygenase-2 (COX-2), we hypothesized that in patients with DM changes in COX-2–dependent prostaglandin synthesis affect vasomotor responses of coronary arterioles. Arterioles were dissected from the right atrial appendages obtained at the time of cardiac surgery of patient with DM(+) or without documented diabetes DM(−). Isolated arterioles (89±15 μm in diameter) were cannulated and pressurized (at 80 mm Hg), and changes in diameter were measured with video microscopy. After spontaneous tone developed [DM(−): 32±7%; DM(+): 37±5%; P =NS], arteriolar responses to bradykinin were investigated. Dilations to bradykinin (0.1 nmol/L to 1 μmol/L) were significantly ( P <0.05) greater in DM(+) than DM(−) patients (10 nmol/L: 77±10% versus 38±14%). In both groups, dilations were similar to the NO-donor, sodium nitroprusside. In arterioles of DM(+), but not those of DM(−), patients’ bradykinin-induced dilations were reduced by the nonselective COX inhibitor indomethacin or by the selective COX-2 inhibitor NS-398 (DM(+) at 10 nmol/L: to 20±4% and 29±7%, respectively). Correspondingly, a marked COX-2 immunostaining was detected in coronary arterioles of DM(+), but not in those of DM(−) patients. We conclude that in coronary arterioles of diabetic patients bradykinin induces enhanced COX-2–derived prostaglandin-mediated dilation. These findings are the first to show that in humans diabetes mellitus increases COX-2 expression and dilator prostaglandin synthesis in coronary arterioles, which may serve to increase dilator capacity and maintain adequate perfusion of cardiac tissues.
- 1 September 2006
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 99 (5) , e12-7
Increased Cyclooxygenase-2 Expression and Prostaglandin-Mediated Dilation in Coronary Arterioles of Patients With Diabetes Mellitus
Based on findings of experimental models of diabetes mellitus (DM) showing increased expression of vascular cyclooxygenase-2 (COX-2), we hypothesized that in patients with DM changes in COX-2–dependent prostaglandin synthesis affect vasomotor responses of coronary arterioles. Arterioles were dissected from the right atrial appendages obtained at the time of cardiac surgery of patient with DM(+) or without documented diabetes DM(−). Isolated arterioles (89±15 μm in diameter) were cannulated and pressurized (at 80 mm Hg), and changes in diameter were measured with video microscopy. After spontaneous tone developed [DM(−): 32±7%; DM(+): 37±5%; P =NS], arteriolar responses to bradykinin were investigated. Dilations to bradykinin (0.1 nmol/L to 1 μmol/L) were significantly ( P <0.05) greater in DM(+) than DM(−) patients (10 nmol/L: 77±10% versus 38±14%). In both groups, dilations were similar to the NO-donor, sodium nitroprusside. In arterioles of DM(+), but not those of DM(−), patients’ bradykinin-induced dilations were reduced by the nonselective COX inhibitor indomethacin or by the selective COX-2 inhibitor NS-398 (DM(+) at 10 nmol/L: to 20±4% and 29±7%, respectively). Correspondingly, a marked COX-2 immunostaining was detected in coronary arterioles of DM(+), but not in those of DM(−) patients. We conclude that in coronary arterioles of diabetic patients bradykinin induces enhanced COX-2–derived prostaglandin-mediated dilation. These findings are the first to show that in humans diabetes mellitus increases COX-2 expression and dilator prostaglandin synthesis in coronary arterioles, which may serve to increase dilator capacity and maintain adequate perfusion of cardiac tissues.
- 1 July 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 148 (5) , 696-702
The levosimendan metabolite OR‐1896 elicits vasodilation by activating the KATPand BKCachannels in rat isolated arterioles
We characterized the vasoactive effects of OR‐1896, the long‐lived metabolite of the inodilator levosimendan, in coronary and skeletal muscle microvessels. The effect of OR‐1896 on isolated, pressurized (80 mmHg) rat coronary and gracilis muscle arteriole (∼150 μm) diameters was investigated by videomicroscopy. OR‐1896 elicited concentration‐dependent (1 nM–10 μM) dilations in coronary (maximal dilation: 66±6%, relative to that in Ca2+‐free solutions; pD2: 7.16±0.42) and gracilis muscle arterioles (maximal dilation: 73±4%; pD2: 6.71±0.42), these dilations proving comparable to those induced by levosimendan (1 nM–10 μM) in coronary (maximal dilation: 83±6%; pD2: 7.06±0.14) and gracilis muscle arterioles (maximal dilation: 73±12%; pD2: 7.05±0.1). The maximal dilations in response to OR‐1896 were significantly (P+channel inhibitor tetraethylammonium (1 mM) in coronary (to 34±9%) and gracilis muscle arterioles (to 28±6%). Glibenclamide (5 or 10 μM), a selective ATP‐sensitive K+channel (KATP) blocker, elicited a greater reduction of OR‐1896‐induced dilations in skeletal muscle arterioles than in coronary microvessels. Conversely, the selective inhibition of the large conductance Ca2+‐activated K+channels (BKCa) with iberiotoxin (100 nM) significantly reduced the OR‐1896‐induced maximal dilation in coronary arterioles (to 21±6%), but was ineffective in skeletal muscle arterioles (72±8%). Accordingly, OR‐1896 elicits a substantial vasodilation in coronary and skeletal muscle arterioles, by activating primarily BKCaand KATPchannels, respectively, and it is suggested that OR‐1896 contributes to the long‐term hemodynamic effects of levosimendan. British Journal of Pharmacology(2006)148, 696–702. doi:10.1038/sj.bjp.0706781
- 1 July 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 148 (5) , 696-702
The levosimendan metabolite OR‐1896 elicits vasodilation by activating the KATPand BKCachannels in rat isolated arterioles
We characterized the vasoactive effects of OR‐1896, the long‐lived metabolite of the inodilator levosimendan, in coronary and skeletal muscle microvessels. The effect of OR‐1896 on isolated, pressurized (80 mmHg) rat coronary and gracilis muscle arteriole (∼150 μm) diameters was investigated by videomicroscopy. OR‐1896 elicited concentration‐dependent (1 nM–10 μM) dilations in coronary (maximal dilation: 66±6%, relative to that in Ca2+‐free solutions; pD2: 7.16±0.42) and gracilis muscle arterioles (maximal dilation: 73±4%; pD2: 6.71±0.42), these dilations proving comparable to those induced by levosimendan (1 nM–10 μM) in coronary (maximal dilation: 83±6%; pD2: 7.06±0.14) and gracilis muscle arterioles (maximal dilation: 73±12%; pD2: 7.05±0.1). The maximal dilations in response to OR‐1896 were significantly (P+channel inhibitor tetraethylammonium (1 mM) in coronary (to 34±9%) and gracilis muscle arterioles (to 28±6%). Glibenclamide (5 or 10 μM), a selective ATP‐sensitive K+channel (KATP) blocker, elicited a greater reduction of OR‐1896‐induced dilations in skeletal muscle arterioles than in coronary microvessels. Conversely, the selective inhibition of the large conductance Ca2+‐activated K+channels (BKCa) with iberiotoxin (100 nM) significantly reduced the OR‐1896‐induced maximal dilation in coronary arterioles (to 21±6%), but was ineffective in skeletal muscle arterioles (72±8%). Accordingly, OR‐1896 elicits a substantial vasodilation in coronary and skeletal muscle arterioles, by activating primarily BKCaand KATPchannels, respectively, and it is suggested that OR‐1896 contributes to the long‐term hemodynamic effects of levosimendan. British Journal of Pharmacology(2006)148, 696–702. doi:10.1038/sj.bjp.0706781
- 1 August 2005
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 25 (8) , 1610-1616
Type 2 Diabetic Mice Have Increased Arteriolar Tone and Blood Pressure
Objective— Type 2 diabetes mellitus (T2-DM) is frequently associated with vascular dysfunction and elevated blood pressure, yet the underlying mechanisms are not completely understood. We hypothesized that in T2-DM, the regulation of peripheral vascular resistance is altered because of changes in local vasomotor mechanisms. Methods and Results— In mice with T2-DM (C57BL/KsJ-db − /db − ), systolic and mean arterial pressures measured by the tail cuff method were significantly elevated compared with those of control (db + /db − ) animals (db/db, 146±5 and 106±2 mm Hg versus control, 133±4 and 98±4 mm Hg, respectively; P −1 [middot]min −1 ). In isolated, pressurized gracilis muscle arterioles (diameter ≈80 μm) from db/db mice, stepwise increases in intraluminal pressure (from 20 to 120 mm Hg) elicited a greater reduction in diameter than in control vessels at each pressure step (at 80 mm Hg, db/db, 66±4% versus control, 79±3%). The passive diameters of arterioles (obtained in Ca 2+ -free solution) and the calculated myogenic index were not significantly different in the 2 groups. The presence of the prostaglandin H 2 /thromboxane A 2 receptor antagonist SQ29548 did not affect arteriolar diameters of control mice but reduced the enhanced arteriolar tone of db/db mice back to control levels (at 80 mm Hg, 80±4%). The inhibitor of cyclooxygenase-1 (COX-1), SC-560, did not affect the basal tone of arterioles, whereas NS-398, an inhibitor of COX-2, caused a significant shift in the arteriolar pressure–diameter curve of vessels from db/db mice (at 80 mm Hg, 76±3%) but not in those of control mice. Also, in aortas of db/db mice, expression of COX-2 was enhanced compared with controls. Conclusions— Collectively, these findings suggest that in mice with T2-DM, the basal tone of skeletal muscle arterioles is increased because of an enhanced COX-2–dependent production of constrictor prostaglandins. These alterations in microvascular prostaglandin synthesis may contribute to the increase in peripheral resistance and blood pressure in T2-DM.
- 1 August 2005
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 25 (8) , 1610-1616
Type 2 Diabetic Mice Have Increased Arteriolar Tone and Blood Pressure
Objective— Type 2 diabetes mellitus (T2-DM) is frequently associated with vascular dysfunction and elevated blood pressure, yet the underlying mechanisms are not completely understood. We hypothesized that in T2-DM, the regulation of peripheral vascular resistance is altered because of changes in local vasomotor mechanisms. Methods and Results— In mice with T2-DM (C57BL/KsJ-db − /db − ), systolic and mean arterial pressures measured by the tail cuff method were significantly elevated compared with those of control (db + /db − ) animals (db/db, 146±5 and 106±2 mm Hg versus control, 133±4 and 98±4 mm Hg, respectively; P −1 [middot]min −1 ). In isolated, pressurized gracilis muscle arterioles (diameter ≈80 μm) from db/db mice, stepwise increases in intraluminal pressure (from 20 to 120 mm Hg) elicited a greater reduction in diameter than in control vessels at each pressure step (at 80 mm Hg, db/db, 66±4% versus control, 79±3%). The passive diameters of arterioles (obtained in Ca 2+ -free solution) and the calculated myogenic index were not significantly different in the 2 groups. The presence of the prostaglandin H 2 /thromboxane A 2 receptor antagonist SQ29548 did not affect arteriolar diameters of control mice but reduced the enhanced arteriolar tone of db/db mice back to control levels (at 80 mm Hg, 80±4%). The inhibitor of cyclooxygenase-1 (COX-1), SC-560, did not affect the basal tone of arterioles, whereas NS-398, an inhibitor of COX-2, caused a significant shift in the arteriolar pressure–diameter curve of vessels from db/db mice (at 80 mm Hg, 76±3%) but not in those of control mice. Also, in aortas of db/db mice, expression of COX-2 was enhanced compared with controls. Conclusions— Collectively, these findings suggest that in mice with T2-DM, the basal tone of skeletal muscle arterioles is increased because of an enhanced COX-2–dependent production of constrictor prostaglandins. These alterations in microvascular prostaglandin synthesis may contribute to the increase in peripheral resistance and blood pressure in T2-DM.